Sep. 16 at 9:06 PM
Barclays initiated coverage on
$JANX at an Overweight rating and
$47 and said, Janux has shown highly encouraging clinical data in late-line metastatic castration-resistant prostate cancer (mCRPC), with Progression-Free Survival (PFS) and Prostate Specific Antigen (PSA) reduction responses outperforming other late-line mCRPC options and competitive with standard of care options in earlier treatment settings.
Given the performance of JANX007 to date, we view the earlier line treatment of prostate cancer with JANX007 as a logical move given its clinical efficacy to date and the economics associated with a large indication like prostate cancer.
$NVS $AMGN $JNJ $AZN